{"id":"cefuroxime-sodium","_fda":{"id":"244117cb-7dfb-44fd-a670-323aae6b51f7","set_id":"0a145288-733a-4966-b7ae-dc96eb103d8c","openfda":{"unii":["R8A7M9MY61"],"route":["INTRAMUSCULAR","INTRAVENOUS"],"rxcui":["1665444","1665449"],"spl_id":["244117cb-7dfb-44fd-a670-323aae6b51f7"],"brand_name":["Cefuroxime sodium"],"spl_set_id":["0a145288-733a-4966-b7ae-dc96eb103d8c"],"package_ndc":["25021-118-10","25021-119-20"],"product_ndc":["25021-118","25021-119"],"generic_name":["CEFUROXIME SODIUM"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CEFUROXIME SODIUM"],"manufacturer_name":["Sagent Pharmaceuticals"],"application_number":["ANDA064125"],"is_original_packager":[true]},"version":"9","warnings":["WARNINGS BEFORE THERAPY WITH CEFUROXIME FOR INJECTION IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. THIS PRODUCT SHOULD BE GIVEN CAUTIOUSLY TO PENICILLIN-SENSITIVE PATIENTS. ANTIBIOTICS SHOULD BE ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMONSTRATED SOME FORM OF ALLERGY, PARTICULARLY TO DRUGS. IF AN ALLERGIC REACTION TO CEFUROXIME FOR INJECTION OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE EPINEPHRINE AND OTHER EMERGENCY MEASURES. Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Cefuroxime for Injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. When the colitis is not relieved by drug discontinuation or when it is severe, oral vancomycin is the treatment of choice for antibiotic-associated pseudomembranous colitis produced by Clostridioides difficile . Other causes of colitis should also be considered."],"pregnancy":["Pregnancy Teratogenic Effects Pregnancy Category B. Reproduction studies have been performed in mice at doses up to 6,400 mg/kg/day (6.3 times the recommended maximum human dose based on mg/m 2 ) and rabbits at doses up to 400 mg/kg/day (2.1 times the recommended maximum human dose based on mg/m 2 ) and have revealed no evidence of impaired fertility or harm to the fetus due to cefuroxime. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed."],"overdosage":["OVERDOSAGE Overdosage of cephalosporins can cause cerebral irritation leading to convulsions. Serum levels of cefuroxime can be reduced by hemodialysis and peritoneal dialysis."],"references":["REFERENCES Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron . 1976; 16:31-41. Brands listed are the trademarks of their respective owners. SAGENT ® Mfd. for SAGENT Pharmaceuticals Schaumburg, IL 60195 (USA) Made in Italy ©2021 Sagent Pharmaceuticals, Inc. Revised: June 2021 SAGENT Pharmaceuticals ®"],"description":["DESCRIPTION Cefuroxime is a sterile semisynthetic, broad-spectrum, cephalosporin antibiotic for parenteral administration. It is the sodium salt of (6R,7R)-3-[(carbamoyloxy)methyl]-7-[[(Z)-(furan-2-yl) (methoxyimino)acetyl] amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, and it has the following chemical structure: The empirical formula is C 16 H 15 N 4 NaO 8 S, representing a molecular weight of 446.37. Cefuroxime for Injection, USP contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity. Cefuroxime for Injection, USP in sterile crystalline form is supplied in vials equivalent to 750 mg or 1.5 g of cefuroxime as cefuroxime sodium. Solutions of Cefuroxime for Injection, USP range in color from light yellow to amber, depending on the concentration and diluent used. The pH of freshly constituted solutions usually ranges from 6 to 8.5. Chemical Structure"],"precautions":["PRECAUTIONS General Although Cefuroxime for Injection rarely produces alterations in kidney function, evaluation of renal status during therapy is recommended, especially in seriously ill patients receiving the maximum doses. Cephalosporins should be given with caution to patients receiving concurrent treatment with potent diuretics as these regimens are suspected of adversely affecting renal function. The total daily dose of Cefuroxime for Injection should be reduced in patients with transient or persistent renal insufficiency (see DOSAGE AND ADMINISTRATION ), because high and prolonged serum antibiotic concentrations can occur in such individuals from usual doses. As with other antibiotics, prolonged use of Cefuroxime for Injection may result in overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken. Broad-spectrum antibiotics should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins. As with other therapeutic regimens used in the treatment of meningitis, mild-to-moderate hearing loss has been reported in a few pediatric patients treated with cefuroxime. Persistence of positive CSF (cerebrospinal fluid) cultures at 18 to 36 hours has also been noted with cefuroxime injection, as well as with other antibiotic therapies; however, the clinical relevance of this is unknown. Cephalosporins may be associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. Prothrombin time should be monitored in patients at risk and exogenous Vitamin K administered as indicated. Prescribing Cefuroxime for Injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Information for Patients Patients should be counseled that antibacterial drugs, including Cefuroxime for Injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Cefuroxime for Injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Cefuroxime for Injection or other antibacterial drugs in the future. Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible. Drug/Laboratory Test Interactions A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedict's or Fehling's solution or with CLINITEST ® tablets) but not with enzyme-based tests for glycosuria. As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood plasma glucose levels in patients receiving Cefuroxime for Injection. Cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method. Carcinogenesis, Mutagenesis, Impairment of Fertility Although lifetime studies in animals have not been performed to evaluate carcinogenic potential, no mutagenic activity was found for cefuroxime in the mouse lymphoma assay and a battery of bacterial mutation tests. Positive results were obtained in an in vitro chromosome aberration assay; however, negative results were found in an in vivo micronucleus test at doses up to 10 g/kg. Reproduction studies in mice at doses up to 3,200 mg/kg/day (3.1 times the recommended maximum human dose based on mg/m 2 ) have revealed no impairment of fertility. Reproductive studies revealed no impairment of fertility in animals. Pregnancy Teratogenic Effects Pregnancy Category B. Reproduction studies have been performed in mice at doses up to 6,400 mg/kg/day (6.3 times the recommended maximum human dose based on mg/m 2 ) and rabbits at doses up to 400 mg/kg/day (2.1 times the recommended maximum human dose based on mg/m 2 ) and have revealed no evidence of impaired fertility or harm to the fetus due to cefuroxime. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers Since cefuroxime is excreted in human milk, caution should be exercised when Cefuroxime for Injection is administered to a nursing woman. Pediatric Use Safety and effectiveness in pediatric patients below 3 months of age have not been established. Accumulation of other members of the cephalosporin class in newborn infants (with resulting prolongation of drug half-life) has been reported. Geriatric Use Of the 1,914 subjects who received cefuroxime in 24 clinical studies of Cefuroxime for Injection, 901 (47%) were 65 years and older while 421 (22%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater susceptibility of some older individuals to drug effects cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION )."],"how_supplied":["HOW SUPPLIED Cefuroxime for Injection, USP is supplied as follows: NDC Cefuroxime for Injection, USP Package Factor 25021-118-10 750 mg equivalent of cefuroxime 25 vials per carton in a Single-Dose Vial 25021-119-20 1.5 grams equivalent of cefuroxime 25 vials per carton in a Single-Dose Vial Cefuroxime for Injection, USP is a dry, white to off-white powder. Storage Conditions Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex."],"microbiology":["Microbiology Mechanism of Action Cefuroxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefuroxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. Mechanism of Resistance Resistance to cefuroxime is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability. Interaction with Other Antimicrobials In an in vitro study antagonistic effects have been observed with the combination of chloramphenicol and cefuroxime. Cefuroxime has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section: Gram-negative bacteria Enterobacter spp. Escherichia coli Klebsiella spp. Haemophilus influenzae Neisseria meningitidis Neisseria gonorrhoeae Gram-positive bacteria Staphylococcus aureus Streptococcus pneumoniae Streptococcus pyogenes The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for cefuroxime against isolates of similar genus or organism group. However, the efficacy of cefuroxime in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials. Gram-negative bacteria Citrobacter spp. Providencia rettgeri Haemophilus parainfluenzae Proteus mirabilis Moraxella catarrhalis Morganella morganii Salmonella spp. Shigella spp. Gram-positive bacteria Staphylococcus epidermidis Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"geriatric_use":["Geriatric Use Of the 1,914 subjects who received cefuroxime in 24 clinical studies of Cefuroxime for Injection, 901 (47%) were 65 years and older while 421 (22%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater susceptibility of some older individuals to drug effects cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION )."],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients below 3 months of age have not been established. Accumulation of other members of the cephalosporin class in newborn infants (with resulting prolongation of drug half-life) has been reported."],"effective_time":"20250204","nursing_mothers":["Nursing Mothers Since cefuroxime is excreted in human milk, caution should be exercised when Cefuroxime for Injection is administered to a nursing woman."],"adverse_reactions":["ADVERSE REACTIONS Cefuroxime for Injection is generally well tolerated. The most common adverse effects have been local reactions following IV administration. Other adverse reactions have been encountered only rarely. Local Reactions Thrombophlebitis has occurred with IV administration in 1 in 60 patients. Gastrointestinal Gastrointestinal symptoms occurred in 1 in 150 patients and included diarrhea (1 in 220 patients) and nausea (1 in 440 patients). The onset of pseudomembranous colitis may occur during or after antibacterial treatment (see WARNINGS ). Hypersensitivity Reactions Hypersensitivity reactions have been reported in fewer than 1% of the patients treated with Cefuroxime for Injection and include rash (1 in 125). Pruritus, urticaria, and positive Coombs' test each occurred in fewer than 1 in 250 patients, and, as with other cephalosporins, rare cases of anaphylaxis, drug fever, erythema multiforme, interstitial nephritis, toxic epidermal necrolysis, and Stevens-Johnson syndrome have occurred. Blood A decrease in hemoglobin and hematocrit has been observed in 1 in 10 patients and transient eosinophilia in 1 in 14 patients. Less common reactions seen were transient neutropenia (fewer than 1 in 100 patients) and leukopenia (1 in 750 patients). A similar pattern and incidence were seen with other cephalosporins used in controlled studies. As with other cephalosporins, there have been rare reports of thrombocytopenia. Hepatic Transient rise in SGOT and SGPT (1 in 25 patients), alkaline phosphatase (1 in 50 patients), LDH (1 in 75 patients), and bilirubin (1 in 500 patients) levels has been noted. Kidney Elevations in serum creatinine and/or blood urea nitrogen and a decreased creatinine clearance have been observed, but their relationship to cefuroxime is unknown. Postmarketing Experience with Cefuroxime for Injection In addition to the adverse events reported during clinical trials, the following events have been observed during clinical practice in patients treated with Cefuroxime for Injection and were reported spontaneously. Data are generally insufficient to allow an estimate of incidence or to establish causation. Immune System Disorders: Cutaneous vasculitis, angioedema, acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction. Nervous System Disorders: Seizure Cephalosporin-class Adverse Reactions In addition to the adverse reactions listed above that have been observed in patients treated with cefuroxime, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: Adverse Reactions Vomiting, abdominal pain, colitis, vaginitis including vaginal candidiasis, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, hemorrhage. Several cephalosporins, including Cefuroxime for Injection, have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced (see DOSAGE AND ADMINISTRATION ). If seizures associated with drug therapy should occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated. Altered Laboratory Tests Prolonged prothrombin time, pancytopenia, agranulocytosis. To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals, Inc. at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ."],"contraindications":["CONTRAINDICATIONS Cefuroxime for Injection is contraindicated in patients with known allergy to the cephalosporin group of antibiotics."],"how_supplied_table":["
NDCCefuroxime for Injection, USPPackage Factor
25021-118-10 750 mg equivalent of cefuroxime 25 vials per carton
in a Single-Dose Vial
25021-119-20 1.5 grams equivalent of cefuroxime 25 vials per carton
in a Single-Dose Vial
"],"general_precautions":["General Although Cefuroxime for Injection rarely produces alterations in kidney function, evaluation of renal status during therapy is recommended, especially in seriously ill patients receiving the maximum doses. Cephalosporins should be given with caution to patients receiving concurrent treatment with potent diuretics as these regimens are suspected of adversely affecting renal function. The total daily dose of Cefuroxime for Injection should be reduced in patients with transient or persistent renal insufficiency (see DOSAGE AND ADMINISTRATION ), because high and prolonged serum antibiotic concentrations can occur in such individuals from usual doses. As with other antibiotics, prolonged use of Cefuroxime for Injection may result in overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken. Broad-spectrum antibiotics should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins. As with other therapeutic regimens used in the treatment of meningitis, mild-to-moderate hearing loss has been reported in a few pediatric patients treated with cefuroxime. Persistence of positive CSF (cerebrospinal fluid) cultures at 18 to 36 hours has also been noted with cefuroxime injection, as well as with other antibiotic therapies; however, the clinical relevance of this is unknown. Cephalosporins may be associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. Prothrombin time should be monitored in patients at risk and exogenous Vitamin K administered as indicated. Prescribing Cefuroxime for Injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria."],"mechanism_of_action":["Mechanism of Action Cefuroxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefuroxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria."],"teratogenic_effects":["Teratogenic Effects Pregnancy Category B. Reproduction studies have been performed in mice at doses up to 6,400 mg/kg/day (6.3 times the recommended maximum human dose based on mg/m 2 ) and rabbits at doses up to 400 mg/kg/day (2.1 times the recommended maximum human dose based on mg/m 2 ) and have revealed no evidence of impaired fertility or harm to the fetus due to cefuroxime. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed."],"storage_and_handling":["Storage Conditions Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY After intramuscular (IM) injection of a 750-mg dose of cefuroxime to normal volunteers, the mean peak serum concentration was 27 mcg/mL. The peak occurred at approximately 45 minutes (range, 15 to 60 minutes). Following IV doses of 750 mg and 1.5 g, serum concentrations were approximately 50 and 100 mcg/mL, respectively, at 15 minutes. Therapeutic serum concentrations of approximately 2 mcg/mL or more were maintained for 5.3 hours and 8 hours or more, respectively. There was no evidence of accumulation of cefuroxime in the serum following IV administration of 1.5-g doses every 8 hours to normal volunteers. The serum half-life after either IM or IV injections is approximately 80 minutes. Approximately 89% of a dose of cefuroxime is excreted by the kidneys over an 8-hour period, resulting in high urinary concentrations. Following the IM administration of a 750-mg single dose, urinary concentrations averaged 1,300 mcg/mL during the first 8 hours. Intravenous doses of 750 mg and 1.5 g produced urinary levels averaging 1,150 and 2,500 mcg/mL, respectively, during the first 8-hour period. The concomitant oral administration of probenecid with cefuroxime slows tubular secretion, decreases renal clearance by approximately 40%, increases the peak serum level by approximately 30%, and increases the serum half-life by approximately 30%. Cefuroxime is detectable in therapeutic concentrations in pleural fluid, joint fluid, bile, sputum, bone, and aqueous humor. Cefuroxime is detectable in therapeutic concentrations in cerebrospinal fluid (CSF) of adults and pediatric patients with meningitis. The following table shows the concentrations of cefuroxime achieved in cerebrospinal fluid during multiple dosing of patients with meningitis. Table 1. Concentrations of Cefuroxime Achieved in Cerebrospinal Fluid During Multiple Dosing of Patients with Meningitis Patients Dose Number of Patients Mean (Range) CSF Cefuroxime Concentrations (mcg/mL) Achieved Within 8 Hours Post Dose Pediatric patients (4 weeks to 6.5 years) 200 mg/kg/day, divided q 6 hours 5 6.6 (0.9 to 17.3) Pediatric patients (7 months to 9 years) 200 to 230 mg/kg/day, divided q 8 hours 6 8.3 (< 2 to 22.5) Adults 1.5 grams q 8 hours 2 5.2 (2.7 to 8.9) Adults 1.5 grams q 6 hours 10 6 (1.5 to 13.5) Cefuroxime is approximately 50% bound to serum protein. Microbiology Mechanism of Action Cefuroxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefuroxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. Mechanism of Resistance Resistance to cefuroxime is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability. Interaction with Other Antimicrobials In an in vitro study antagonistic effects have been observed with the combination of chloramphenicol and cefuroxime. Cefuroxime has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section: Gram-negative bacteria Enterobacter spp. Escherichia coli Klebsiella spp. Haemophilus influenzae Neisseria meningitidis Neisseria gonorrhoeae Gram-positive bacteria Staphylococcus aureus Streptococcus pneumoniae Streptococcus pyogenes The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for cefuroxime against isolates of similar genus or organism group. However, the efficacy of cefuroxime in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials. Gram-negative bacteria Citrobacter spp. Providencia rettgeri Haemophilus parainfluenzae Proteus mirabilis Moraxella catarrhalis Morganella morganii Salmonella spp. Shigella spp. Gram-positive bacteria Staphylococcus epidermidis Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"indications_and_usage":["INDICATIONS AND USAGE Cefuroxime for Injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections , including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase- producing strains), Streptococcus pyogenes , and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. Skin and Skin-Structure Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , Escherichia coli, Klebsiella spp., and Enterobacter spp. Septicemia caused by Staphylococcus aureus (penicillinase- and non-penicillinase- producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis , and Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains) in both males and females. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non- penicillinase-producing strains). Clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime for Injection, USP has been used successfully in these mixed infections in which several organisms have been isolated. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefuroxime for Injection, USP may be used concomitantly with an aminoglycoside (see PRECAUTIONS ). The recommended doses of both antibiotics may be given depending on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection, USP and other antibacterial drugs, Cefuroxime for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Prevention The preoperative prophylactic administration of Cefuroxime for Injection, USP may prevent the growth of susceptible disease-causing bacteria and thereby may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures (e.g., vaginal hysterectomy) that are classified as clean-contaminated or potentially contaminated procedures. Effective prophylactic use of antibiotics in surgery depends on the time of administration. Cefuroxime for Injection, USP should usually be given one-half to 1 hour before the operation to allow sufficient time to achieve effective antibiotic concentrations in the wound tissues during the procedure. The dose should be repeated intraoperatively if the surgical procedure is lengthy. Prophylactic administration is usually not required after the surgical procedure ends and should be stopped within 24 hours. In the majority of surgical procedures, continuing prophylactic administration of any antibiotic does not reduce the incidence of subsequent infections but will increase the possibility of adverse reactions and the development of bacterial resistance. The perioperative use of Cefuroxime for Injection, USP has also been effective during open heart surgery for surgical patients in whom infections at the operative site would present a serious risk. For these patients it is recommended that therapy with Cefuroxime for Injection, USP be continued for at least 48 hours after the surgical procedure ends. If an infection is present, specimens for culture should be obtained for the identification of the causative organism, and appropriate antimicrobial therapy should be instituted."],"information_for_patients":["Information for Patients Patients should be counseled that antibacterial drugs, including Cefuroxime for Injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Cefuroxime for Injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Cefuroxime for Injection or other antibacterial drugs in the future. Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible."],"spl_unclassified_section":["SAGENT ® Rx only To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection and other antibacterial drugs, Cefuroxime for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.","COMPATIBILITY AND STABILITY Intramuscular When constituted as directed with Sterile Water for Injection, suspensions of cefuroxime for IM injection maintain satisfactory potency for 24 hours at room temperature and for 48 hours under refrigeration (5°C). After the periods mentioned above any unused suspensions should be discarded. Intravenous When the 750-mg and 1.5-g vials are constituted as directed with Sterile Water for Injection, the solutions of Cefuroxime for Injection for IV administration maintain satisfactory potency for 24 hours at room temperature and for 48 hours (750-mg and 1.5-g vials) under refrigeration (5°C). More dilute solutions, such as 750 mg or 1.5 g plus 100 mL of Sterile Water for Injection, 5% Dextrose Injection, or 0.9% Sodium Chloride Injection, also maintain satisfactory potency for 24 hours at room temperature and for 7 days under refrigeration. These solutions may be further diluted to concentrations of between 1 and 30 mg/mL in the following solutions and will lose not more than 10% activity for 24 hours at room temperature or for at least 7 days under refrigeration: 0.9% Sodium Chloride Injection; 1/6 M Sodium Lactate Injection; Ringer's Injection, USP; Lactated Ringer's Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection; 5% Dextrose Injection; 5% Dextrose and 0.45% Sodium Chloride Injection; 5% Dextrose and 0.225% Sodium Chloride Injection; 10% Dextrose Injection; and 10% Invert Sugar in Water for Injection. Unused solutions should be discarded after the time periods mentioned above. Cefuroxime for Injection has also been found compatible for 24 hours at room temperature when admixed in IV infusion with heparin (10 and 50 U/mL) in 0.9% Sodium Chloride Injection and Potassium Chloride (10 and 40 mEq/L) in 0.9% Sodium Chloride Injection. Sodium Bicarbonate Injection, USP is not recommended for the dilution of Cefuroxime for Injection. Frozen Stability Constitute the 750-mg or 1.5-g vial as directed for IV administration in Table 3 . Immediately withdraw the total contents of the 750-mg or 1.5-g vial and add to a compatible container containing 50 or 100 mL of 0.9% Sodium Chloride Injection or 5% Dextrose Injection and freeze. Frozen solutions are stable for 6 months when stored at -20°C. Frozen solutions should be thawed at room temperature and not refrozen. Do not force thaw by immersion in water baths or by microwave irradiation. Thawed solutions may be stored for up to 24 hours at room temperature or for 7 days in a refrigerator. Note : Parenteral drug products should be inspected visually for particulate matter and discoloration before administration whenever solution and container permit. As with other cephalosporins, Cefuroxime for Injection powder as well as solutions and suspensions tend to darken, depending on storage conditions, without adversely affecting product potency."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Dosage Adults The usual adult dosage range for Cefuroxime for Injection is 750 mg to 1.5 grams every 8 hours, usually for 5 to 10 days. In uncomplicated urinary tract infections, skin and skin-structure infections, disseminated gonococcal infections, and uncomplicated pneumonia, a 750-mg dose every 8 hours is recommended. In severe or complicated infections, a 1.5-gram dose every 8 hours is recommended. In bone and joint infections, a 1.5-gram dose every 8 hours is recommended. In clinical trials, surgical intervention was performed when indicated as an adjunct to therapy with Cefuroxime for Injection. A course of oral antibiotics was administered when appropriate following the completion of parenteral administration of Cefuroxime for Injection. In life-threatening infections or infections due to less susceptible organisms, 1.5 grams every 6 hours may be required. In bacterial meningitis, the dosage should not exceed 3 grams every 8 hours. The recommended dosage for uncomplicated gonococcal infection is 1.5 grams given intramuscularly as a single dose at 2 different sites together with 1 gram of oral probenecid. For preventive use for clean-contaminated or potentially contaminated surgical procedures, a 1.5-gram dose administered intravenously just before surgery (approximately one-half to 1 hour before the initial incision) is recommended. Thereafter, give 750 mg intravenously or intramuscularly every 8 hours when the procedure is prolonged. For preventive use during open heart surgery, a 1.5-gram dose administered intravenously at the induction of anesthesia and every 12 hours thereafter for a total of 6 grams is recommended. Impaired Renal Function A reduced dosage must be employed when renal function is impaired. Dosage should be determined by the degree of renal impairment and the susceptibility of the causative organism (see Table 2 ). Table 2. Dosage of Cefuroxime for Injection in Adults with Reduced Renal Function a Since Cefuroxime for Injection is dialyzable, patients on hemodialysis should be given a further dose at the end of the dialysis. Creatinine Clearance (mL/min) Dose Frequency > 20 750 mg to 1.5 grams q8h 10 to 20 750 mg q12h < 10 750 mg q24h a When only serum creatinine is available, the following formula 1 (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal function. NOTE: As with antibiotic therapy in general, administration of Cefuroxime for Injection should be continued for a minimum of 48 to 72 hours after the patient becomes asymptomatic or after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended in infections caused by Streptococcus pyogenes in order to guard against the risk of rheumatic fever or glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary tract infection and may be required for several months after therapy has been completed; persistent infections may require treatment for several weeks; and doses smaller than those indicated above should not be used. In staphylococcal and other infections involving a collection of pus, surgical drainage should be carried out where indicated. Equation Pediatric Patients Above 3 Months of Age Administration of 50 to 100 mg/kg/day in equally divided doses every 6 to 8 hours has been successful for most infections susceptible to cefuroxime. The higher dosage of 100 mg/kg/day (not to exceed the maximum adult dosage) should be used for the more severe or serious infections. In bone and joint infections, 150 mg/kg/day (not to exceed the maximum adult dosage) is recommended in equally divided doses every 8 hours. In clinical trials, a course of oral antibiotics was administered to pediatric patients following the completion of parenteral administration of Cefuroxime for Injection. In cases of bacterial meningitis, a larger dosage of Cefuroxime for Injection is recommended, 200 to 240 mg/kg/day intravenously in divided doses every 6 to 8 hours. In pediatric patients with renal insufficiency, the frequency of dosing should be modified consistent with the recommendations for adults. Preparation of Solution and Suspension The directions for preparing Cefuroxime for Injection for both IV and IM use are summarized in Table 3 . For Intramuscular Use Each 750-mg vial of Cefuroxime for Injection should be constituted with 3 mL of Sterile Water for Injection. Shake gently to disperse and withdraw completely the resulting suspension for injection. For Intravenous Use Each 750-mg vial should be constituted with 8.3 mL of Sterile Water for Injection. Withdraw completely the resulting solution for injection. Each 1.5-gram vial should be constituted with 16 mL of Sterile Water for Injection, and the solution should be completely withdrawn for injection. Table 3. Preparation of Solution and Suspension a Note: Cefuroxime for Injection is a suspension at IM concentrations. Strength Amount of Diluent to be Added (mL) Volume to be Withdrawn Approximate Cefuroxime Concentration (mg/mL) 750-mg Vial 3 (IM) Total a 225 750-mg Vial 8.3 (IV) Total 90 1.5-gram Vial 16 (IV) Total 90 Administration After constitution, Cefuroxime for Injection may be given intravenously or by deep IM injection into a large muscle mass (such as the gluteus or lateral part of the thigh). Before injecting intramuscularly, aspiration is necessary to avoid inadvertent injection into a blood vessel. Intravenous Administration The IV route may be preferable for patients with bacterial septicemia or other severe or life-threatening infections or for patients who may be poor risks because of lowered resistance, particularly if shock is present or impending. For direct intermittent IV administration , slowly inject the solution into a vein over a period of 3 to 5 minutes or give it through the tubing system by which the patient is also receiving other IV solutions. For intermittent IV infusion with a Y-type administration set , dosing can be accomplished through the tubing system by which the patient may be receiving other IV solutions. However, during infusion of the solution containing Cefuroxime for Injection, it is advisable to temporarily discontinue administration of any other solutions at the same site. For continuous IV infusion , a solution of Cefuroxime for Injection may be added to an IV infusion pack containing one of the following fluids: 0.9% Sodium Chloride Injection; 5% Dextrose Injection; 10% Dextrose Injection; 5% Dextrose and 0.9% Sodium Chloride Injection; 5% Dextrose and 0.45% Sodium Chloride Injection; or 1/6 M Sodium Lactate Injection. Solutions of Cefuroxime for Injection, like those of most beta-lactam antibiotics, should not be added to solutions of aminoglycoside antibiotics because of potential interaction. However, if concurrent therapy with Cefuroxime for Injection and an aminoglycoside is indicated, each of these antibiotics can be administered separately to the same patient."],"spl_product_data_elements":["Cefuroxime sodium Cefuroxime sodium cefuroxime sodium cefuroxime Cefuroxime sodium Cefuroxime sodium cefuroxime sodium cefuroxime"],"clinical_pharmacology_table":["
Table 1. Concentrations of Cefuroxime Achieved in Cerebrospinal Fluid During Multiple Dosing of Patients with Meningitis
Patients Dose Number of PatientsMean (Range) CSF Cefuroxime Concentrations (mcg/mL) Achieved Within 8 Hours Post Dose
Pediatric patients (4 weeks to 6.5 years) 200 mg/kg/day, divided q 6 hours 5 6.6 (0.9 to 17.3)
Pediatric patients (7 months to 9 years) 200 to 230 mg/kg/day, divided q 8 hours 6 8.3 (< 2 to 22.5)
Adults 1.5 grams q 8 hours 2 5.2 (2.7 to 8.9)
Adults 1.5 grams q 6 hours 10 6 (1.5 to 13.5)
"],"dosage_and_administration_table":["
Table 2. Dosage of Cefuroxime for Injection in Adults with Reduced Renal Function
a Since Cefuroxime for Injection is dialyzable, patients on hemodialysis should be given a further dose at the end of the dialysis.
Creatinine Clearance (mL/min)DoseFrequency
> 20 750 mg to 1.5 grams q8h
10 to 20 750 mg q12h
< 10 750 mg q24ha
","
Table 3. Preparation of Solution and Suspension
a Note: Cefuroxime for Injection is a suspension at IM concentrations.
StrengthAmount of Diluent to be Added (mL)Volume to be WithdrawnApproximate Cefuroxime Concentration (mg/mL)
750-mg Vial 3 (IM) Totala225
750-mg Vial 8.3 (IV) Total 90
1.5-gram Vial 16 (IV) Total 90
"],"package_label_principal_display_panel":["PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label NDC 25021-119-20 Rx only CEFUROXIME FOR INJECTION, USP 1.5 grams per vial Equivalent to 1.5 grams of cefuroxime activity Single-Dose Vial For Intravenous Use PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label","PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label NDC 25021-118-10 Rx only CEFUROXIME FOR INJECTION, USP 750 mg per vial Equivalent to 750 mg of cefuroxime activity Single-Dose Vial For Intravenous or Intramuscular Use PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label"],"drug_and_or_laboratory_test_interactions":["Drug/Laboratory Test Interactions A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedict's or Fehling's solution or with CLINITEST ® tablets) but not with enzyme-based tests for glycosuria. As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood plasma glucose levels in patients receiving Cefuroxime for Injection. Cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Although lifetime studies in animals have not been performed to evaluate carcinogenic potential, no mutagenic activity was found for cefuroxime in the mouse lymphoma assay and a battery of bacterial mutation tests. Positive results were obtained in an in vitro chromosome aberration assay; however, negative results were found in an in vivo micronucleus test at doses up to 10 g/kg. Reproduction studies in mice at doses up to 3,200 mg/kg/day (3.1 times the recommended maximum human dose based on mg/m 2 ) have revealed no impairment of fertility. Reproductive studies revealed no impairment of fertility in animals."]},"safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"local reactions (thrombophlebitis)","drugRate":"1 in 60","_validated":true,"placeboRate":""},{"effect":"gastrointestinal symptoms","drugRate":"1 in 150","_validated":true,"placeboRate":""},{"effect":"diarrhea","drugRate":"1 in 220","_validated":true,"placeboRate":""},{"effect":"nausea","drugRate":"1 in 440","_validated":true,"placeboRate":""},{"effect":"rash","drugRate":"1 in 125","_validated":true,"placeboRate":""},{"effect":"pruritus","drugRate":"fewer than 1 in 250","_validated":true,"placeboRate":""},{"effect":"urticaria","drugRate":"fewer than 1 in 250","_validated":true,"placeboRate":""},{"effect":"positive Coombs' test","drugRate":"fewer than 1 in 250","_validated":true,"placeboRate":""},{"effect":"decrease in hemoglobin and hematocrit","drugRate":"1 in 10","_validated":true,"placeboRate":""},{"effect":"transient eosinophilia","drugRate":"1 in 14","_validated":true,"placeboRate":""},{"effect":"transient neutropenia","drugRate":"fewer than 1 in 100","_validated":true,"placeboRate":""},{"effect":"leukopenia","drugRate":"1 in 750","_validated":true,"placeboRate":""},{"effect":"transient rise in SGOT","drugRate":"1 in 25","_validated":true,"placeboRate":""},{"effect":"transient rise in SGPT","drugRate":"1 in 25","_validated":true,"placeboRate":""},{"effect":"transient rise in alkaline phosphatase","drugRate":"1 in 50","_validated":true,"placeboRate":""},{"effect":"transient rise in LDH","drugRate":"1 in 75","_validated":true,"placeboRate":""},{"effect":"transient rise in bilirubin","drugRate":"1 in 500","_validated":true,"placeboRate":""}],"contraindications":["Cefuroxime for Injection is contraindicated in patients with known allergy to the cephalosporin group of antibiotics."]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CEFUROXIME SODIUM","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:40:55.399139+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:41:01.820772+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFUROXIME SODIUM","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:41:02.551152+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:40:53.221030+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:42:33.060508+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:40:53.221066+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"Mechanism of Action Cefuroxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefuroxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:41:14.479466+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial penicillin-binding protein inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:41:03.703918+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2146124/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:41:03.600981+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS Cefuroxime for Injection is generally well tolerated. The most common adverse effects have been local reactions following IV administration. Other adverse reactions have been encountered only rarely. Local Reactions Thrombophlebitis has occurred with IV administration in 1 in 60 patients. Gastrointestinal Gastrointestinal symptoms occurred in 1 in 150 patients and included diarrhea (1 in 220 patients) and nausea (1 in 440 patients). The onset of pseudomembranous colitis may occ","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:41:45.230294+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:41:48.216098+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA064125","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:40:53.221071+00:00"}},"_dailymed":{"setId":"0a145288-733a-4966-b7ae-dc96eb103d8c","title":"CEFUROXIME SODIUM INJECTION, POWDER, FOR SOLUTION [SAGENT PHARMACEUTICALS]"},"mechanism":{"explanation":"Cefuroxime works by preventing bacteria from building their cell walls, which leads to the death of the bacteria. It can still be effective even when some bacteria produce enzymes that break down similar antibiotics.","oneSentence":"Cefuroxime inhibits bacterial cell wall synthesis, acting as a bactericidal agent.","technicalDetail":"Cefuroxime inhibits bacterial cell wall synthesis, which is essential for bacterial survival. It remains active in the presence of certain beta-lactamases, including penicillinases and cephalosporinases, produced by both Gram-negative and Gram-positive bacteria."},"_scrapedAt":"2026-03-27T23:31:52.654Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T05:42:33.602125+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"cefuroxime-sodium-lower-respiratory-tract-infect","name":"Lower Respiratory Tract Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with infections caused by susceptible strains of the designated organisms","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with infections caused by susceptible strains of the designated organisms","diagnosticRequired":null,"brandNameForIndication":""},{"id":"cefuroxime-sodium-urinary-tract-infections","name":"Urinary Tract Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with infections caused by susceptible strains of the designated organisms","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with infections caused by susceptible strains of the designated organisms","diagnosticRequired":null,"brandNameForIndication":""},{"id":"cefuroxime-sodium-skin-and-skin-structure-infect","name":"Skin and Skin-Structure Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with infections caused by susceptible strains of the designated organisms","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with infections caused by susceptible strains of the designated organisms","diagnosticRequired":null,"brandNameForIndication":""},{"id":"cefuroxime-sodium-septicemia","name":"Septicemia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with infections caused by susceptible strains of the designated organisms","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with infections caused by susceptible strains of the designated organisms","diagnosticRequired":null,"brandNameForIndication":""},{"id":"cefuroxime-sodium-meningitis","name":"Meningitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with infections caused by susceptible strains of the designated organisms","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with infections caused by susceptible strains of the designated organisms","diagnosticRequired":null,"brandNameForIndication":""},{"id":"cefuroxime-sodium-gonorrhea","name":"Gonorrhea","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Both males and females with infections caused by susceptible strains of the designated organisms","pivotalTrial":null,"restrictions":[],"patientPopulation":"Both males and females with infections caused by susceptible strains of the designated organisms","diagnosticRequired":null,"brandNameForIndication":""},{"id":"cefuroxime-sodium-bone-and-joint-infections","name":"Bone and Joint Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with infections caused by susceptible strains of the designated organisms","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with infections caused by susceptible strains of the designated organisms","diagnosticRequired":null,"brandNameForIndication":""},{"id":"cefuroxime-sodium-preoperative-prophylaxis","name":"Preoperative Prophylaxis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients undergoing surgical procedures classified as clean-contaminated or potentially contaminated","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients undergoing surgical procedures classified as clean-contaminated or potentially contaminated","diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT07033039","phase":"NA","title":"Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre","status":"RECRUITING","sponsor":"University of Nove de Julho","startDate":"2026-01-30","conditions":"Rhinoplasty, Edema","enrollment":60},{"nctId":"NCT06406114","phase":"PHASE2","title":"Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-05-05","conditions":"Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity","enrollment":300},{"nctId":"NCT05750966","phase":"NA","title":"Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-07-19","conditions":"Cholangitis","enrollment":440},{"nctId":"NCT07267013","phase":"PHASE2","title":"Clindamycin as an Alternative to Vancomycin in Patients Undergoing Aortic Cardiac Surgery With Extracorporeal Circulation (ECC)","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-03-30","conditions":"Aortic Surgery, Extracorporeal Circulation","enrollment":25},{"nctId":"NCT07346742","phase":"NA","title":"Prevention of Surgical Site Infection in Open Paediatric Groin Surgeries Using Intravenous Prophylactic Antibiotics and Antimicrobial-coated Sutures","status":"RECRUITING","sponsor":"Olawumi Olajide","startDate":"2025-03-09","conditions":"Inguinal Hernia, Hydroceles, Surgical Site Infection","enrollment":174},{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":"Febrile Urinary Tract Infection","enrollment":560},{"nctId":"NCT06663527","phase":"NA","title":"Compound Phellodendron Decoction May Promote Wound Healing After Anal Fistulotomy","status":"COMPLETED","sponsor":"The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine","startDate":"2024-10-26","conditions":"Fistula in Ano","enrollment":60},{"nctId":"NCT03935828","phase":"PHASE2","title":"Effect of Topical Sinonasal Antibiotics","status":"WITHDRAWN","sponsor":"United States Naval Medical Center, San Diego","startDate":"2019-06","conditions":"Chronic Rhinosinusitis (Diagnosis), Antibiotic Side Effect","enrollment":""},{"nctId":"NCT05157113","phase":"PHASE4","title":"Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-05-31","conditions":"Cataract, Surgery, Compliance, Patient","enrollment":70},{"nctId":"NCT05530174","phase":"NA","title":"Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With a Fracture","status":"ACTIVE_NOT_RECRUITING","sponsor":"Soren Overgaard","startDate":"2022-09-01","conditions":"Fracture of Hip, Total Hip Arthroplasty, Prosthetic-joint Infection","enrollment":2000},{"nctId":"NCT05530551","phase":"NA","title":"Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With OA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Soren Overgaard","startDate":"2022-09-01","conditions":"Osteoarthritis, Hip, Total Hip Arthroplasty, Prosthetic-joint Infection","enrollment":20000},{"nctId":"NCT06709196","phase":"PHASE4","title":"Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-01-07","conditions":"Cystectomy, Bladder Cancer Requiring Cystectomy, Postoperative Infections","enrollment":248},{"nctId":"NCT05502380","phase":"PHASE3","title":"Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery","status":"RECRUITING","sponsor":"Balgrist University Hospital","startDate":"2022-09-15","conditions":"Surgical Site Infection, Microbial Colonization, Antibiotic Resistant Infection","enrollment":1100},{"nctId":"NCT05784311","phase":"PHASE4","title":"Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2023-03-06","conditions":"Pancreatic Cancer","enrollment":344},{"nctId":"NCT06527560","phase":"PHASE4","title":"Clinical Trial Comparing Oral Versus Intravenous Cefuroxime in Pregnant Women with Pyelonephritis","status":"RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2024-09-09","conditions":"Pyelonephritis in Pregnancy","enrollment":100},{"nctId":"NCT05337566","phase":"NA","title":"Does Additional Use of Preoperative Azithromycin Decrease Posthysterectomy Infections","status":"RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2022-09-05","conditions":"Infection Post Op, Hysterectomy, Antibiotics","enrollment":2278},{"nctId":"NCT05609240","phase":"PHASE2","title":"Colo-Pro_2: Bolus-continuous Infusion Cefuroxime Prophylaxis for the Prevention of Infections After Colorectal Surgery","status":"RECRUITING","sponsor":"University of Leeds","startDate":"2023-05-10","conditions":"Antibiotic Prophylaxis, Colorectal Surgery","enrollment":180},{"nctId":"NCT06351891","phase":"PHASE4","title":"Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-04","conditions":"Helicobacter Pylori Infection","enrollment":248},{"nctId":"NCT02538991","phase":"NA","title":"TVT Versus Bulkamid®-Injections in Treatment of Stress Urinary Incontinence","status":"ACTIVE_NOT_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2015-09","conditions":"Urinary Stress Incontinence","enrollment":224},{"nctId":"NCT04510558","phase":"NA","title":"Reducing the Incidence of Incisional Hernia After Stoma Closure Using a Prophylactic Mesh","status":"UNKNOWN","sponsor":"University Hospital, Geneva","startDate":"2021-05-01","conditions":"Incisional Hernia","enrollment":72},{"nctId":"NCT01581047","phase":"","title":"Pharmacokinetics of Small Spectrum Beta-lactam Antibiotics (Amoxicillin/Clavulanic Acid and Cefuroxime) in Patients on Intensive Care Units","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2012-03-15","conditions":"Infection","enrollment":37},{"nctId":"NCT04378868","phase":"PHASE4","title":"Role of Delay and Antibiotics on Perforation Rate While Waiting Appendectomy","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2020-05-18","conditions":"Appendicitis","enrollment":1800},{"nctId":"NCT05398081","phase":"PHASE2","title":"Cefuroxime vs Ceftriaxone for SSI Prevention in Neurosurgery","status":"COMPLETED","sponsor":"Dr. Promise Tamunoipiriala Jaja","startDate":"2021-12-01","conditions":"Surgical Site Infection, Antibiotics Prophylaxis","enrollment":96},{"nctId":"NCT02800785","phase":"NA","title":"The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-05","conditions":"Appendicitis","enrollment":1552},{"nctId":"NCT04303390","phase":"PHASE4","title":"24 Vs 48 Hours of Cefazolin or Cefuroxime as Prophylaxis","status":"COMPLETED","sponsor":"Saud Al Babtain Cardiac Center","startDate":"2018-02-06","conditions":"Surgical Site Infection","enrollment":568},{"nctId":"NCT03108690","phase":"PHASE4","title":"Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia","status":"WITHDRAWN","sponsor":"Sara Thønnings","startDate":"2017-10-01","conditions":"Bacteremia","enrollment":""},{"nctId":"NCT05711810","phase":"PHASE4","title":"Medicine-induced Cardiac Hemodialysis on COVID-19","status":"COMPLETED","sponsor":"Yang I. Pachankis","startDate":"2023-01-02","conditions":"Severe Acute Respiratory Syndrome-related Coronavirus, Renal Dialysis, Vaccines","enrollment":1},{"nctId":"NCT03877289","phase":"PHASE4","title":"Efficacy of Oxybutynin in Paediatric Cystitis","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2008-10","conditions":"Cystitis","enrollment":81},{"nctId":"NCT04479657","phase":"EARLY_PHASE1","title":"Qingfei Granule for the Treatment of the Pediatric Acute Upper Respiratory Tract Infection With Bacterial Infection","status":"UNKNOWN","sponsor":"Zhong Wang","startDate":"2020-10-17","conditions":"Upper Respiratory Tract Infection, Bacterial Infection, Chinese Medicine","enrollment":60},{"nctId":"NCT04723472","phase":"NA","title":"Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment","status":"SUSPENDED","sponsor":"Shanghai East Hospital","startDate":"2023-08-01","conditions":"Helicobacter Pylori Infection","enrollment":82},{"nctId":"NCT05606302","phase":"","title":"A Multi-center Clinical Study of Drug Antibody and Precision Transfusion in China","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2021-10-01","conditions":"Drug-specific Antibodies","enrollment":14000},{"nctId":"NCT05577273","phase":"NA","title":"Does Antibiotic Prophylaxis at Urinary Catheter Removal Prevent Urinary Tract Infections","status":"UNKNOWN","sponsor":"Omri Schwarztuch Gildor","startDate":"2018-08-14","conditions":"Urologic Diseases, Urinary Tract Disease","enrollment":1000},{"nctId":"NCT04470973","phase":"","title":"Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Patients.","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2020-07-15","conditions":"Sepsis, Septic Shock, Infection, Bacterial","enrollment":40},{"nctId":"NCT05388747","phase":"","title":"Population Pharmacokinetics, Effectiveness and Safety of Cefuroxime in Neonates","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2022-05-16","conditions":"Infectious Disease","enrollment":100},{"nctId":"NCT04161599","phase":"PHASE4","title":"Preoperative Oral Antibiotics With vs Without Mechanical Bowel Preparation to Reduce Surgical Site Infections Following Colonic Resection: an International Randomized Controlled Trial.","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2022-03-01","conditions":"Wounds and Injuries, Surgery--Complications","enrollment":968},{"nctId":"NCT05200975","phase":"NA","title":"Target Attainment of Cefuroxim","status":"UNKNOWN","sponsor":"Noordwest Ziekenhuisgroep","startDate":"2022-01-15","conditions":"Infection, Bacterial, Kinesics","enrollment":45},{"nctId":"NCT05293977","phase":"NA","title":"Short-Term Use of Antibiotics and Adherence Level","status":"COMPLETED","sponsor":"Jordan University of Science and Technology","startDate":"2020-08-03","conditions":"Acute Infection","enrollment":589},{"nctId":"NCT00000752","phase":"PHASE2","title":"Preventing Frequent Sinus Infections in HIV-Infected Patients","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Sinusitis","enrollment":""},{"nctId":"NCT02972944","phase":"NA","title":"Laparoscopic Cholecystectomy or Conservative Treatment in the Acute Cholecystitis of Elderly Patients","status":"UNKNOWN","sponsor":"Kuopio University Hospital","startDate":"2016-10","conditions":"Cholecystitis, Acute","enrollment":200},{"nctId":"NCT04616352","phase":"","title":"Cefuroxime Resistance in Pyelonephritis","status":"COMPLETED","sponsor":"Universidad Nacional de Colombia","startDate":"2020-12-26","conditions":"Urinary Tract Infections","enrollment":973},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT03657836","phase":"NA","title":"The Sublimated Mare Milk Supplement's Effect on Gut Mucosal Lining After Antibiotics","status":"COMPLETED","sponsor":"Nazarbayev University Medical Center","startDate":"2018-08-01","conditions":"Acute Bronchitis","enrollment":12},{"nctId":"NCT04212078","phase":"PHASE1, PHASE2","title":"Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime","status":"UNKNOWN","sponsor":"National University of Malaysia","startDate":"2019-07-29","conditions":"Endophthalmitis Postoperative","enrollment":138},{"nctId":"NCT03716804","phase":"PHASE4","title":"Establish the Relationship Between Shift in Prescribing Pattern and Associated Shift in Sensitivity Pattern of Causative Microbes in UTI Patients in a Closed Community","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2018-06-06","conditions":"Uncomplicated Urinary Tract Infection, Antibiotic Resistant Infection","enrollment":62},{"nctId":"NCT02795949","phase":"PHASE3","title":"Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2016-10","conditions":"Enterobacteriaceae Infections","enrollment":344},{"nctId":"NCT02916134","phase":"NA","title":"Conservative Versus Operative ManageMent of Acute Uncomplicated Appendicitis","status":"COMPLETED","sponsor":"Beaumont Hospital","startDate":"2016-09-12","conditions":"Appendicitis","enrollment":186},{"nctId":"NCT01507974","phase":"NA","title":"Examination of the Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2012-01-16","conditions":"Pregnancy Complications","enrollment":220},{"nctId":"NCT04321902","phase":"NA","title":"Empirical Antibiotics in Acute Inflammatory Gallbladder Disease","status":"UNKNOWN","sponsor":"Seoul St. Mary's Hospital","startDate":"2020-04-02","conditions":"Cholecystitis, Acute","enrollment":350},{"nctId":"NCT04295122","phase":"PHASE4","title":"Comparing the Effectiveness of Phacoemulsification + ECP Laser and Phacoemulsification Alone for Glaucoma Patients","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2020-03-15","conditions":"Glaucoma Open-Angle Primary, Cataract","enrollment":160},{"nctId":"NCT02505581","phase":"PHASE4","title":"Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-05","conditions":"Surgical Wound Infection","enrollment":536},{"nctId":"NCT02445859","phase":"PHASE2","title":"Continuous Antibiotic Prophylaxis in Colorectal Surgery","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2015-08","conditions":"Surgical Site Infection","enrollment":90},{"nctId":"NCT02789579","phase":"EARLY_PHASE1","title":"The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2016-09","conditions":"Complication of Surgical Procedure","enrollment":150},{"nctId":"NCT04055233","phase":"PHASE3","title":"Reduction of Postoperative Wound Infections by Antiseptica?","status":"COMPLETED","sponsor":"Johannes Lauscher","startDate":"2015-02-01","conditions":"Surgical Site Infection","enrollment":456},{"nctId":"NCT02297815","phase":"","title":"Comparative Effectiveness of Antibiotics for Respiratory Infections","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2014-01","conditions":"Acute Otitis Media, Acute Sinusitis, Group A Streptococcal Pharyngitis","enrollment":2472},{"nctId":"NCT04009772","phase":"PHASE2, PHASE3","title":"Single Dose Cefepime Versus Cefuroxime Plus Metronidazole as a Prophylactic Antibiotic During Emergency Intrapartum Cesarean Section","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-07-01","conditions":"Emergency Cesarean Section, Infection Wound","enrollment":500},{"nctId":"NCT01659866","phase":"PHASE4","title":"Antibiotic Prophylaxis for Transrectal Prostate Biopsy","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2012-08","conditions":"Infection","enrollment":563},{"nctId":"NCT03980015","phase":"","title":"Inflammatory Responses in Solitary and Multiple Erythema Migrans","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2006-06-01","conditions":"Erythema Migrans","enrollment":134},{"nctId":"NCT02147249","phase":"NA","title":"Cytokines and Chemokines in Erythema Migrans","status":"UNKNOWN","sponsor":"University Medical Centre Ljubljana","startDate":"2013-07","conditions":"Erythema Migrans","enrollment":150},{"nctId":"NCT02850250","phase":"","title":"Pharmacokinetics of Post Operative Cefuroxime in Infants Undergoing Cardiac Surgery","status":"WITHDRAWN","sponsor":"Alder Hey Children's NHS Foundation Trust","startDate":"2018-07","conditions":"Cardiac Event","enrollment":""},{"nctId":"NCT03754387","phase":"NA","title":"Antibiotic Therapy vs Laparscopic Appendectomy in Pediatric Chronic Appendicitis","status":"UNKNOWN","sponsor":"Zunyi Medical College","startDate":"2019-01-01","conditions":"Chronic Appendicitis","enrollment":200},{"nctId":"NCT03014687","phase":"PHASE4","title":"Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions","status":"RECRUITING","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2017-07-01","conditions":"Antibiotics, Pituitary Adenoma","enrollment":116},{"nctId":"NCT02515565","phase":"NA","title":"Physiotherapy in Patients Hospitalized Due to Pneumonia.","status":"UNKNOWN","sponsor":"Universidad de Granada","startDate":"2015-09","conditions":"Pneumonia","enrollment":60},{"nctId":"NCT03584919","phase":"NA","title":"Comparison of Doxycycline and Cefuroxime Axetil in Erythema Migrans","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2006-06-01","conditions":"Erythema Chronicum Migrans","enrollment":509},{"nctId":"NCT03221504","phase":"NA","title":"7-day Compared With 10-day Antibiotic Treatment for Febrile Urinary Tract Infections in Children","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2018-01-01","conditions":"Urinary Tract Infections in Children","enrollment":221},{"nctId":"NCT03141476","phase":"PHASE4","title":"Adequacy of Perioperative Cefuroxime Dosage According to the BMI","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2017-03-01","conditions":"Obesity; Drug","enrollment":60},{"nctId":"NCT03020940","phase":"","title":"The Clinical Trial of Cefuroxime Axetil Dispersible Tablets","status":"UNKNOWN","sponsor":"Jiangsu Famous Medical Technology Co., Ltd.","startDate":"2017-01","conditions":"Infectious Disease","enrollment":100000},{"nctId":"NCT02819570","phase":"PHASE4","title":"Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes","status":"UNKNOWN","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2015-11","conditions":"Premature Rupture of Membrane","enrollment":400},{"nctId":"NCT01790529","phase":"PHASE4","title":"Randomized Controlled Trial to Evaluate the Optimal Timing of Surgical Antimicrobial Prophylaxis","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2013-02","conditions":"Surgical Site Infection","enrollment":5000},{"nctId":"NCT00497341","phase":"PHASE4","title":"Antibiotic Prophylaxis in Total Knee Prosthesis","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2008-01","conditions":"Infection","enrollment":1332},{"nctId":"NCT00136344","phase":"NA","title":"Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract Surgery","status":"COMPLETED","sponsor":"City, University of London","startDate":"2003-09","conditions":"Endophthalmitis","enrollment":35000},{"nctId":"NCT01259141","phase":"NA","title":"The Optimization of Mycoplasm Pneumonia Antibiotic Therapy","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2010-10","conditions":"Mycoplasma Pneumonia","enrollment":208},{"nctId":"NCT02436083","phase":"PHASE4","title":"Antibiotics in Free Flaps Reconstructions","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2007-07","conditions":"Postoperative Infection","enrollment":350},{"nctId":"NCT02009098","phase":"PHASE4","title":"RCT of Postoperative Infections Following Caesarean Section Infections Following Caesarean Section","status":"WITHDRAWN","sponsor":"Odense University Hospital","startDate":"2014-10","conditions":"Postoperative Infection","enrollment":""},{"nctId":"NCT02162134","phase":"NA","title":"Does Sugared or Sugar Free Chewing Gum Reduces Postoperative Ileus After Laparoscopic Cholecystectomy","status":"COMPLETED","sponsor":"Benazir Bhutto Hospital, Rawalpindi","startDate":"2013-01","conditions":"Postoperative Ileus.","enrollment":90},{"nctId":"NCT01587768","phase":"","title":"WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11","conditions":"Infections, Bacterial","enrollment":1},{"nctId":"NCT01283815","phase":"PHASE2","title":"Laparoscopic Management of Periappendicular Abscess","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2011-01","conditions":"Appendicitis, Abdominal Abscess","enrollment":60},{"nctId":"NCT02171338","phase":"PHASE4","title":"Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections","status":"UNKNOWN","sponsor":"Holbaek Sygehus","startDate":"2013-10","conditions":"Pneumonia, Acute Exacerbation of Chronic Obstructive Airways Disease","enrollment":55},{"nctId":"NCT02072798","phase":"PHASE4","title":"Antibiotics and Gut Microbiota Among Newborn Infants","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2014-02","conditions":"Surgical Wound Infection, Infection; Cesarean Section, Complications; Cesarean Section","enrollment":42},{"nctId":"NCT01434173","phase":"","title":"Risk of Acute Liver Injury in Users of Antimicrobials","status":"COMPLETED","sponsor":"Bayer","startDate":"2001-07","conditions":"Drug-Induced Liver Injury","enrollment":1299056},{"nctId":"NCT02169856","phase":"NA","title":"Role of Emotional Freedom Techniques in Reducing Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy","status":"COMPLETED","sponsor":"Benazir Bhutto Hospital, Rawalpindi","startDate":"2013-07","conditions":"Postoperative Nausea and Vomiting","enrollment":50},{"nctId":"NCT00492973","phase":"NA","title":"Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?","status":"COMPLETED","sponsor":"New Lexington Clinic","startDate":"2006-03","conditions":"Osteoarthritis, Post-traumatic; Arthrosis","enrollment":101},{"nctId":"NCT00818610","phase":"PHASE4","title":"Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Swiss National Fund for Scientific Research","startDate":"2009-01","conditions":"Community-acquired Pneumonia","enrollment":601},{"nctId":"NCT00901628","phase":"PHASE4","title":"Periarticular Multimodal Drug Injections in Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2008-04","conditions":"Osteoarthritis, Knee","enrollment":101},{"nctId":"NCT00613769","phase":"PHASE4","title":"Orally Administered Trimethoprim-sulfamethoxazole and Metronidazole as Prophylaxis of Infection Following Elective Colorectal Surgery","status":"COMPLETED","sponsor":"Halmstad County Hospital","startDate":"2007-09","conditions":"Infection Prophylaxis in Colo Rectal Surgery","enrollment":1073},{"nctId":"NCT01080963","phase":"PHASE4","title":"Daptomycin as Antibiotic Prophylaxis of Sternal Wound Infections","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2008-11","conditions":"Wound Infection","enrollment":650},{"nctId":"NCT01524081","phase":"PHASE3","title":"Antibiotic Prophylaxis in the Prevention of Surgical Site Infections After Selected Urgent Abdominal Surgical Procedures","status":"COMPLETED","sponsor":"The Faculty Hospital Na Bulovce","startDate":"2008-07","conditions":"Acute Appendicitis, Perforated Gastroduodenal Ulcer, Small Bowel Obstruction","enrollment":187},{"nctId":"NCT01518192","phase":"PHASE4","title":"Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2006-06","conditions":"Erythema Migrans, Post-Lyme Disease Symptoms","enrollment":544},{"nctId":"NCT01372371","phase":"NA","title":"Efficacy of Local Powder Prophylactics","status":"UNKNOWN","sponsor":"Ganga Hospital","startDate":"2011-06","conditions":"Infection","enrollment":1844},{"nctId":"NCT00269932","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Cefuroxime Axetil in the Treatment of Adults With Persistent Bronchitis Experiencing Rapid Onset of Severe Worsening of Symptoms Caused by Bacteria","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1993-08","conditions":"Bronchitis, Chronic","enrollment":485},{"nctId":"NCT00257049","phase":"PHASE2, PHASE3","title":"A Study of the Safety and Effectiveness of Levofloxacin Compared With Ceftriaxone Sodium or Cefuroxime Axetil in the Treatment of Adults With Pneumonia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1984-01","conditions":"Pneumonia","enrollment":604},{"nctId":"NCT00132938","phase":"PHASE4","title":"PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-01","conditions":"Chronic Bronchitis","enrollment":5660},{"nctId":"NCT01237730","phase":"NA","title":"Tailored Antibiotics Prophylaxis for Percutaneous Endoscopic Gastrostomy","status":"UNKNOWN","sponsor":"National Cheng Kung University","startDate":"2010-07","conditions":"The Patients Who Receive Percutaneous Endoscopic Gastrostomy, Peristomal Wound Infection After the Operation of PEG, Prophylactic Antibiotics Before PEG","enrollment":100},{"nctId":"NCT01228825","phase":"","title":"Pharmacokinetics of Cefuroxime in Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2007-05","conditions":"Cardiac Surgery","enrollment":19},{"nctId":"NCT00557453","phase":"","title":"The Role of Antibiotic Treatment in Patients With Acute Mild Cholecystitis - A Prospective Randomized Controlled Trial","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2008-04","conditions":"Acute Cholecystitits","enrollment":120},{"nctId":"NCT01138852","phase":"PHASE4","title":"Ampicillin/Sulbactam Versus Cefuroxime as Antimicrobial Prophylaxis for Cesarean Section","status":"COMPLETED","sponsor":"Attikon Hospital","startDate":"2004-07","conditions":"Surgical Site Infections","enrollment":176},{"nctId":"NCT00174811","phase":"PHASE3","title":"Comparative Study to Evaluate the Efficacy and Safety of Telithromycin Given Once Daily Versus Cefuroxime Axetil Given Twice Daily in Children With Middle Ear Infections","status":"TERMINATED","sponsor":"Sanofi","startDate":"2005-06","conditions":"Otitis Media","enrollment":639},{"nctId":"NCT00355602","phase":"NA","title":"Antibiotics for the Treatment of Ulcerative Colitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-07","conditions":"Colitis, Ulcerative","enrollment":40},{"nctId":"NCT00730938","phase":"NA","title":"The Effect of Intracameral Cefuroxime on Post-op Fibrin in Pediatric Cataract Surgery","status":"COMPLETED","sponsor":"Presbyterian Church East Africa Kikuyu Hospital","startDate":"2008-02","conditions":"Cataract, Endophthalmitis","enrollment":45},{"nctId":"NCT00713999","phase":"NA","title":"Urogenital Schistosomiasis and Sexually Transmitted Infections in Madagascar","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2001-08","conditions":"Sexually Transmitted Infections, Schistosoma Haematobium","enrollment":680},{"nctId":"NCT00648726","phase":"PHASE3","title":"An Open, Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin Versus Cefuroxime Alone or With Oral Erythromycin for the Treatment of Chinese Patients Who Were Hospitalized for Pneumonia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-01","conditions":"Pneumonia","enrollment":139}],"_emaApprovals":[],"_faersSignals":[{"count":153,"reaction":"DYSPNOEA"},{"count":132,"reaction":"HYPERSENSITIVITY"},{"count":131,"reaction":"OFF LABEL USE"},{"count":107,"reaction":"HEADACHE"},{"count":100,"reaction":"CONDITION AGGRAVATED"},{"count":89,"reaction":"ANXIETY"},{"count":88,"reaction":"ANGIOEDEMA"},{"count":88,"reaction":"PAIN IN EXTREMITY"},{"count":88,"reaction":"SWELLING FACE"},{"count":86,"reaction":"HAEMOPTYSIS"}],"administration":{"route":"Intramuscular"},"crossReferences":{"chemblId":"CHEMBL2146124"},"_approvalHistory":[{"date":"20160412","type":"SUPPL","sponsor":"ACS DOBFAR SPA","applicationNumber":"ANDA064125"},{"date":"20211008","type":"SUPPL","sponsor":"ACS DOBFAR SPA","applicationNumber":"ANDA064125"},{"date":"20070131","type":"SUPPL","sponsor":"ACS DOBFAR SPA","applicationNumber":"ANDA064125"},{"date":"19970530","type":"ORIG","sponsor":"ACS DOBFAR SPA","applicationNumber":"ANDA064125"},{"date":"20040823","type":"SUPPL","sponsor":"ACS DOBFAR SPA","applicationNumber":"ANDA064125"},{"date":"19990923","type":"SUPPL","sponsor":"ACS DOBFAR SPA","applicationNumber":"ANDA064125"},{"date":"20121121","type":"SUPPL","sponsor":"ACS DOBFAR SPA","applicationNumber":"ANDA064125"}],"publicationCount":141,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"CEFUROXIME SODIUM","genericName":"CEFUROXIME SODIUM","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1983","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T05:42:33.602125+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}